Bone mineral density of patients with chronic plaque psoriasis

被引:37
作者
Millard, TP
Antoniades, L
Evans, AV
Smith, HR
Spector, TD
Barker, JNWN
机构
[1] St Thomas Hosp, St Johns Inst Dermatol, London, England
[2] St Thomas Hosp, Twin Res & Genet Epidemiol Unit, London, England
关键词
D O I
10.1046/j.1365-2230.2001.00855.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Reduced bone mineral density (BMD), the major risk factor for osteoporotic fracture. has been linked to palmoplantar pustular psoriasis, but no significant studies have examined BMD in chronic plaque psoriasis (CPP). In this study, in-patients with severe CPP had their BMD measured at the nondominant hip and lumbar spine using dual energy X-ray absorbtiometry. Ten male and 10 female Caucasian patients were recruited, with a mean age of 47 years (range 20-71 years). There were no significant differences in BMD between patients and controls. However, patients with psoriatic arthropathy in addition to CPP had a significantly lower mean lumbar spine Z-score (- 1.16) than those without arthropathy (+ 1.38, P = 0.015). Neither previous nor current treatment with systemic steroids, retinoids or methotrexate significantly affected BMD. We found no evidence that patients with CPP despite risk factors, have a significantly low BMD, although the subgroup with joint involvement appear be at significantly higher risk of osteoporosis and may therefore require preventative treatment.
引用
收藏
页码:446 / 448
页数:3
相关论文
共 17 条
  • [1] ANDREW T, 2001, IN PRESS GENESCREEN
  • [2] Buckley LM, 1997, J RHEUMATOL, V24, P1489
  • [3] ALTERATIONS IN APPENDICULAR SKELETAL MASS IN PATIENTS WITH RHEUMATOID, PSORIATIC, AND OSTEOARTHROPATHY
    COOPER, C
    POLL, V
    MCLAREN, M
    DAUNT, SO
    CAWLEY, MID
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1988, 47 (06) : 481 - 484
  • [4] BONE-DENSITY AT VARIOUS SITES FOR PREDICTION OF HIP-FRACTURES
    CUMMINGS, SR
    BLACK, DM
    NEVITT, MC
    BROWNER, W
    CAULEY, J
    ENSRUD, K
    GENANT, HK
    PALERMO, L
    SCOTT, J
    VOGT, TM
    [J]. LANCET, 1993, 341 (8837) : 72 - 75
  • [5] DESILVA BD, 1999, BRIT J DERMATOL, V141, P85
  • [6] OSTEOPOROSIS IS A TOXIC EFFECT OF LONG-TERM ETRETINATE THERAPY
    DIGIOVANNA, JJ
    SOLLITTO, RB
    ABANGAN, DL
    STEINBERG, SM
    REYNOLDS, JC
    [J]. ARCHIVES OF DERMATOLOGY, 1995, 131 (11) : 1263 - 1267
  • [7] Treatment of postmenopausal osteoporosis
    Eastell, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (11) : 736 - 746
  • [8] MARKERS OF BONE METABOLISM IN POSTMENOPAUSAL WOMEN WITH RHEUMATOID-ARTHRITIS - EFFECTS OF CORTICOSTEROIDS AND HORMONE REPLACEMENT THERAPY
    HALL, GM
    SPECTOR, TD
    DELMAS, PD
    [J]. ARTHRITIS AND RHEUMATISM, 1995, 38 (07): : 902 - 906
  • [9] PERSPECTIVE - THE DIAGNOSIS OF OSTEOPOROSIS
    KANIS, JA
    MELTON, LJ
    CHRISTIANSEN, C
    JOHNSTON, CC
    KHALTAEV, N
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1994, 9 (08) : 1137 - 1141
  • [10] DRUG-INDUCED OSTEOPOROSIS
    MAZANEC, DJ
    GRISANTI, JM
    [J]. CLEVELAND CLINIC JOURNAL OF MEDICINE, 1989, 56 (03) : 297 - 303